Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of methiopropamine can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of methiopropamine can be broken down into several components which progressively intensify proportional to dosage. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Moderately addictive with high potential for abuse and capable of causing psychological dependence. Compulsive redosing is commonly reported, particularly with insufflation or vaporization routes, though generally considered less severe than substances like MDPV or mephedrone.
Cravings and withdrawal effects may occur following cessation of chronic use, though physical dependence appears less prominent than psychological dependence.
The exact toxic dosage is unknown. One death attributed solely to methiopropamine toxicity has been reported in a 29-year-old male with a peripheral blood level of 38 mg/L postmortem. Other fatalities have involved polydrug use, including combinations with methoxetamine and flubromazepam.
Cardiovascular stimulation including chest tightness, chest pains, racing heart, vasoconstriction, and palpitations are somewhat common at higher doses and with repeated dosing; serious cardiovascular events appear to be associated with overdose or extreme use patterns rather than typical recreational use.
Labored breathing and pain with deep breaths have been reported, primarily at higher doses or with repeated dosing.
Capable of producing stimulant psychosis with symptoms including paranoia, visual and auditory hallucinations, delusions, and incoherent speech. Risk is significantly elevated by high doses, repeated dosing, and accompanying sleep deprivation. Case reports document paranoid delusions, dysmorphophobia, and self-harming behavior in affected users.
Methiopropamine was first synthesized and reported in 1942. The work was primarily conducted at the University of Michigan, with limited pharmacological evaluation carried out at Parke Davis pharmaceutical company. This early research demonstrated that the compound possessed substantial pressor
As of 2018, not specifically scheduled under federal legislation. May still be subject to analog provisions in some states.
Not specifically scheduled, but may be considered an illicit analog under the Controlled Drugs and Substances Act due to structural similarity to methamphetamine.
Classified as an illegal substance under Finnish drug legislation.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since July 17, 2013. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited.
Initially placed under a Temporary Class Drug Order on November 27, 2015, following recommendation by the Advisory Council on the Misuse of Drugs. After the TCDO demonstrated effectiveness in reducing availability and harm indicators, MPA was permanently added to the Misuse of Drugs Act 1971 as a Class B substance on November 27, 2017.
Controlled under the Suchtmittelgesetz (Narcotics Act) since June 26, 2019. Possession, production, and sale are prohibited.
Added to the list of controlled substances by the China Food and Drug Administration effective October 1, 2015.
Classified as a stupéfiant, the French designation for recognized drugs of abuse with the highest level of control. Possession, purchase, sale, and manufacture are illegal.
Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics regulations.
Not scheduled at the federal level. However, the DEA has noted it is a 2-thienyl analog of the Schedule II substance methamphetamine, and prosecution under the Federal Analogue Act is possible if sold for human consumption. The structural differences from methamphetamine (five-member sulfur-containing ring versus benzene ring) make analogue status legally uncertain. State-level controls exist in Florida (Schedule I since December 2012) and Arizona (listed as a dangerous drug since April 2014).
16 sources cited
